You are here: Industry Insights > Eli Lilly

News List

Lilly's $7M tax abatement in Indianapolis draws bipartisan pushback fiercepharma
March 20, 2019
Eli Lilly rolled out an $850 million investment plan for the U.S. two years ago, with a chunk of that earmarked for its hometown. But one of those Indianapolis building projects is getting some pushback now, thanks to a local tax break approved Monday eve
Lilly’s combo therapy succeeds in late-stage lung cancer study expressbpd
March 13, 2019
Lung cancer is the leading cause of cancer death among both men and women, according to the American Cancer Society
Lilly answers insulin price-hike critics with 50% off Humalog generic fiercepharma
March 07, 2019
Eli Lilly CEO David Ricks' absence from last week’s Senate Finance Committee hearing on drug prices didn’t go unnoticed.
Lilly to Introduce Lower-Priced Insulin americanpharmaceuticalreview
March 06, 2019
Eli Lilly and Company announced the company will introduce a lower-priced version of Humalog® (insulin lispro injection 100 units/mL) in the United States, providing people with diabetes an insulin option that will have a list price 50 percent lower than
Eli Lilly to Sell Cheaper Version of Insulin Drug drugs
March 05, 2019
A cheaper version of Eli Lilly's most popular insulin drug, Humalog, is being introduced by the drug maker.
Eli Lilly to launch authorised Humalog generic in the US at 50-percent lower list price firstwordpharma
March 04, 2019
Eli Lilly said Monday that it will launch an authorised generic version of Humalog (insulin lispro) in the US at a 50-percent lower list price than the original branded product as part of efforts to address the issue of patients' high out-of-pocket costs.
Eli Lilly’s surprise Lartruvo failure, Loxo buy put a dent in its 2019 hopes fiercepharma
February 24, 2019
It was not so long ago, Dec. 19 to be exact, that Eli Lilly thrilled investors with 2019 revenue and earnings projections that far exceeded what analysts were expecting.
Insulin pricing lawsuit against Sanofi, Novo Nordisk and Eli Lilly moves forward fiercepharma
February 24, 2019
Insulin giants are facing unprecedented scrutiny for their pricing, thanks to a growing gap between their retail stickers and prices after behind-the-scenes discounts and rebates. And now they'll have to face class-action claims about those very practices
FDA expands Lilly's ALIMTA Label biospectrumasia
February 02, 2019
This indication is approved based on data from Merck's Phase 3 KEYNOTE-189 trial
No bidding war for Loxo, so did Lilly overpay? Don’t rush to judgment, analysts say fiercepharma
January 21, 2019
When Eli Lilly announced during the recent J.P. Morgan Healthcare Conference that it would buy Loxo Oncology for $8 billion—a 68% premium—some analysts assumed there must have been a bidding war for the developer of targeted cancer drugs. But SEC document

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page